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Summary
Background Nevirapine given once-daily for the ﬁ rst 6, 14, or 28 weeks of life to infants exposed to HIV-1 
via breastfeeding reduces transmission through this route compared with single-dose nevirapine at birth or neonatally. 
We aimed to assess incremental safety and eﬃ  cacy of extension of such prophylaxis to 6 months.
Methods In our phase 3, randomised, double-blind, placebo-controlled HPTN 046 trial, we assessed the incremental 
beneﬁ t of extension of once-daily infant nevirapine from age 6 weeks to 6 months. We enrolled breastfeeding infants 
born to mothers with HIV-1 in four African countries within 7 days of birth. Following receipt of nevirapine from 
birth to 6 weeks, infants without HIV infection were randomly allocated (by use of a computer-generated permuted 
block algorithm with random block sizes and stratiﬁ ed by site and maternal antiretroviral treatment status) to receive 
extended nevirapine prophylaxis or placebo until 6 months or until breastfeeding cessation, whichever came ﬁ rst. 
The primary eﬃ  cacy endpoint was HIV-1 infection in infants at 6 months and safety endpoints were adverse reactions 
in both groups. We used Kaplan-Meier analyses to compare diﬀ erences in the primary outcome between groups. 
This study is registered with ClinicalTrials.gov, number NCT00074412.
Findings Between June 19, 2008, and March 12, 2010, we randomly allocated 1527 infants (762 nevirapine and 
765 placebo); ﬁ ve of whom had HIV-1 infection at randomisation and were excluded from the primary analyses. In 
Kaplan-Meier analysis, 1·1% (95% CI 0·3–1·8) of infants who received extended nevirapine developed HIV-1 between 
6 weeks and 6 months compared with 2·4% (1·3–3·6) of controls (diﬀ erence 1·3%, 95% CI 0–2·6), equating to a 
54% reduction in transmission (p=0·049). However, mortality (1·2% for nevirapine vs 1·1% for placebo; p=0·81) and 
combined HIV infection and mortality rates (2·3% vs 3·2%; p=0·27) did not diﬀ er between groups at 6 months. 
125 (16%) of 758 infants given extended nevirapine and 116 (15%) of 761 controls had serious adverse events, but 
frequency of adverse events, serious adverse events, and deaths did not diﬀ er signiﬁ cantly between treatment groups. 
Interpretation Nevirapine prophylaxis can safely be used to provide protection from mother-to-child transmission of 
HIV-1 via breastfeeding for infants up to 6 months of age.
Funding US National Institutes of Health.
Introduction
Breastfeeding in sub-Saharan Africa provides vital 
nutrition for infants between birth and 24 months of age 
and provides protection against respiratory and diarrhoeal 
illnesses, leading to improved overall survival. However, 
breastfeeding up to 24 months of age in infants exposed 
to HIV can account for 30–40% of all mother-to-child 
transmission.1,2 Therefore, although prophylactic ante-
partum and intrapartum antiretroviral regimens can 
substantially reduce in utero and intrapartum mother-to-
child transmission, these substantial gains are lost in 
breastfeeding populations in whom infants have con-
tinued exposure to HIV-1 from breast milk.3,4
Extended regimens of 6, 14, and 28 weeks’ nevirapine 
are eﬀ ective in infants for reduction of postnatal HIV-1 
transmission, as is 6 months of postnatal triple-drug 
prophylaxis for mothers.5–8 However, strategies for 
prevention of mother-to-child transmission (PMTCT) 
require extensive, coordinated services and postnatal 
prevention regimens can be costly. Moreover, in many 
settings infants exposed to HIV-1 are lost to follow-up 
after the ﬁ rst postpartum visit.9 Consequently, postnatal 
prophy lactic antiretroviral regimens for PMTCT have 
been diﬃ  cult to implement in many low-income settings, 
despite WHO guidelines recommending extended 
breastf eeding for infants exposed to HIV-1 until the age 
of 12 months together with antiretroviral prophylaxis for 
the mother or infant for the duration of breast feeding.10,11
Implementation of the complete cascade of PMTCT 
services, including routine HIV screening of pregnant 
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women, provision of antiretroviral interventions during 
pregnancy, labour, and delivery, and during breastfeeding, 
and linkage to long-term care and treatment services for 
HIV infected mothers in low-income settings is crucial 
to substantially reduce global perinatal HIV-1 infection.12 
Implicit in such eﬀ orts is an assessment of the absolute 
eﬀ ectiveness of every step of the PMTCT cascade, 
including antiretroviral inter ventions during breast-
feeding. The duration of published infant prophylaxis 
regimens ranges from several weeks to several months, 
and the infrastructure investments needed for every 
regimen can vary widely, which might aﬀ ect the feasibility 
of provision of these interventions. We aimed to assess 
the incremental eﬃ  cacy and safety of extension of once-
daily nevirapine until the age of 6 months in African 
infants exposed to HIV-1 during breastfeeding who had 
already received 6 weeks of once-daily nevirapine.
Methods
Study design and participants
HPTN 046 was a phase 3, randomised, double-blind, 
placebo-controlled trial that assessed the eﬃ  cacy and 
safety of extension of once-daily nevirapine to 6 months 
of age or until cessation of breastfeeding (whichever 
came ﬁ rst) for prevention of transmission in HIV-1-
exposed breastfeeding infants who had received 
nevirapine prophylaxis until the age of 6 weeks.
Women were recruited from antenatal clinics in 
Durban in South Africa, Dar es Salaam in Tanzania, 
Kampala in Uganda, and Chitungwiza in Zimbabwe, 
where HIV-1 testing, counselling, and the local standard 
of care antiretroviral regimen for PMTCT were provided. 
All women provided written informed consent. Eligible 
women and infants were enrolled within 7 days of 
delivery. Primary eligibility criteria included maternal 
age (≥18 years), infant HIV-1 DNA PCR negative from a 
specimen obtained within 7 days of birth, and 
birthweight of 2000 g or more. We excluded women and 
infants if either had a serious medical disorder that 
would interfere with study participation. Women 
receiving antiretroviral drugs for HIV-1 treatment or for 
PMTCT were eligible. Infant study visits were 
undertaken within 7 days postpartum, at 2, 5, 6, and 
8 weeks, and at 3, 6, 9, 12, and 18 months. Infants who 
developed HIV-1 infections were taken oﬀ  study drug 
and referred for additional care and treatment.
The study protocol was approved by at least one local 
ethics review committee aﬃ  liated with every study site, 
by committees aﬃ  liated with US collaborating institutions, 
and by other local regulatory bodies where applicable.
Randomisation and masking
All enrolled infants received once-daily open-label 
nevirapine (10 mg/mL oral suspension) for the ﬁ rst 
6 weeks of life. After such treatment (at age 6–8 weeks), 
we randomly allocated eligible infants in a one-to-one ratio 
to receive extended nevirapine (treatment group) or 
placebo (control group) according to computer-generated 
permutated block algorithms by site with random block 
sizes. Because maternal receipt of anti retroviral drugs can 
aﬀ ect postnatal transmission, infants were stratiﬁ ed by 
maternal antiretroviral treatment status at randomisa-
tion.8,13 Infants had to be HIV-1 DNA PCR negative on a 
specimen obtained within 21 days before randomisation 
and still breastfeeding, with the mother’s intent to 
continue breastfeeding. An independent contractor in the 
USA provided identical, sealed, individual study drug kits, 
which were prepared and labelled centrally according to 
the random allocation assignment generated by the HPTN 
Statistical and Data Management Center (Seattle, WA, 
USA). These kits were sent to the study sites for sequential 
assignment to infants as they were randomised. Study 
staﬀ  and participants were masked to the study drug 
(nevirapine or placebo) assignment.
Procedures
Women gave study drug to their children with calibrated 
oral syringes. Randomly allocated infants started masked 
study drug and continued a once-daily dosing regimen 
until 6 months of age or until cessation of breastfeeding, 
whichever came ﬁ rst. The nevirapine dose was increased 
with age, ranging from 20 mg once-daily after 6–8 weeks 
of age to 28 mg once-daily after 5–6 months of age. Women 
were counselled to exclusively breastfeed for 6 months.
The primary eﬃ  cacy endpoint was HIV-1 infection at 
age 6 months in infants who were uninfected at age 
6 weeks in each study group. Primary safety endpoints 
were frequency and severity of adverse reactions in 
randomly allocated infants until age 6 months in each 
group for all infants who received at least one dose of 
study intervention. Secondary endpoints included HIV-1-
free survival, relative rates of HIV-1 infection, and infant 
survival rates (mortality irrespective of HIV-1 infection) in 
the two study groups.
We tested infants for HIV-1 infection at 3, 6, 9, 12, and 
18 months. Infant blood was stored at randomisation and 
tested retrospectively in those who had HIV-1-infection at 
the 3 month visit. Infants identiﬁ ed as HIV-1-infected at 
6 weeks were excluded from analysis of primary and 
secondary endpoints. We deﬁ ned HIV-1 infection as two 
separate peripheral blood specimens drawn on diﬀ erent 
days that were positive by HIV-1 DNA PCR. HIV-1 DNA 
was measured at site laboratories with the Roche 
AMPLICOR HIV-1 DNA test, version 1.5 (Roche Molecular 
Systems, Branchburg, NJ, USA); all laboratories partici-
pated in the Virology Quality Assurance Program (Rush 
Medical College, Chicago, IL, USA) sponsored by the 
Division of AIDS (DAIDS) of the US National Institute of 
Allergy and Infectious Diseases (NIAID).
We graded clinical and laboratory adverse events 
according to the DAIDS table for grading of the severity of 
adult and paediatric adverse events (version 1.0; 
December, 2004, with clariﬁ cation dated August, 2009). 
We used a separate grading scale for rash, malnutrition, 
For the study protocol see 
http://www.hptn.org/web%20
documents/HPTN_Protocols/
HPTN046/HPTN046v3.pdf
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and fever in infants. The three scales were adapted from 
diﬀ erent sources; the rash grading scale was adapted from 
standard NIAID/DAIDS rash grading; the malnutrition 
scale was adapted from the WHO deﬁ nitions associated 
with malnutrition; and the fever scale was based on the 
standard NIAID/DAIDS grading, with adjustment for 
axillary measurement. We reported all adverse events 
(serious and non-serious) up to age 8 months (8 weeks 
after maximum study drug dosing); thereafter, only 
serious adverse events were reported. We assessed 
breastfeeding status at every infant visit and cessation was 
established by maternal report of last date of infant breast-
milk exposure. All infants had reached age 6 months (for 
ascertainment of the primary study endpoints) by 
July, 2010, and 12 months of age by January, 2011. Our 
present analyses are for data obtained by the 12 month 
visit. Follow-up of infants is continuing to 18 months of 
age for further assessment of secondary endpoints.
Statistical analysis
On the basis of results from the Six Week Extended-Dose 
Nevirapine (SWEN) study,5 we assumed that the overall 
rate of HIV-1 infection in the placebo group would be 
about 2·6% at age 6 weeks and about 6·7% at age 
6 months, giving a cumulative infection rate of 4·2% 
between these ages in the control group. We estimated 
that 1500 mother-infant pairs would provide 90% power 
to detect a reduction in HIV-1 infection from 4·2% to 
1·4% at age 6 months with a Pearson χ² test statistic and 
a one-sided false positive error rate of 0·025.
We summarised baseline characteristics with means 
and proportions. We calculated rates of cumulative 
infection, death, and HIV-1-free survival by randomisation 
group at 6, 9, and 12 months with the Kaplan-Meier 
method, and 95% CIs with Greenwood’s formula. We 
compared cumulative rates with the Z statistic. Time of 
HIV-1 infection was deﬁ ned as the midpoint between the 
last negative and the ﬁ rst positive HIV-1 test. For the 
cumulative-infection analysis, infants with no positive 
tests were censored at the time of last negative test. For 
HIV-1-free survival, the event time was the minimum of 
the infection time and the death time with censoring at 
the last negative test if no positive test or death was 
reported. We also created Kaplan-Meier curves of time to 
breastfeeding cessation, with comparisons between 
groups done with the log-rank test. Reported p values and 
CIs have not been adjusted for interim analyses or multiple 
comparisons. All statistical analyses were performed using 
SAS version 9.0 for UNIX.
This study is registered with ClinicalTrials.gov, number 
NCT00074412.
Role of the funding source
The sponsor (US National Institutes of Health) 
participated in the design and oversight of the study, 
interpretation of the results, and preparation of the 
manuscript. The sponsor also provided for an 
inde pendent data and safety monitoring board to review 
the trial every 6 months. Members of the writing team 
had full access to the study data. The protocol chair, co-
chairs, and sponsor representatives had ﬁ nal respon-
sibility for the decision to submit for publication.
Results
We randomly allocated 1527 infants aged 6 weeks, born 
to 1505 women with HIV-1 infection, between June 19, 
2008, and March 12, 2010  (ﬁ gure 1). Five infants had 
HIV-1 infection at the time of randomisation and 
were excluded from the primary analyses. Baseline 
1700 infants enrolled
173 excluded
4 lost to follow-up before 6 weeks
7 deaths before 6 weeks (3 infants 
and 4 mothers)
162 other*
50 stopped breastfeeding
21 intended to stop breastfeeding 
before 6 months
25 adverse events
17 missed randomisation window
7 HIV infection
23 parents refusal
2 concomitant use of rifampicin
10 relocated
7 other†
1527 infants randomised
762 randomly allocated to receive nevirapine
759 infants did not have HIV infection 
at randomisation
3 infants had HIV infection at randomisation
765 randomly allocated to receive placebo
763 infants did not have HIV infection
at randomisation
2 infants had HIV infection at randomisation
759 included in primary analysis
758 started study drug
608 completed 6 months’ drug dosing
150 discontinued study drug early
8 died
9 adverse events
2 HIV infection
97 discontinued breastfeeding
6 parents refusal
28 other
1 did not start study drug
759 known antiretroviral status at randomisation
537 no antiretroviral therapy
0 non-HAART antiretroviral therapy
222 HAART
HIV infection status at 6 months
729 known
30 not known
9 infant deaths
21 lost to follow-up
763 included in primary analysis
761 started placebo
608 completed 6 months’ placebo
153 discontinued placebo early
5 died
11 adverse events
7 HIV infection
93 discontinued breastfeeding
7 parents refusal
30 other
2 did not start placebo
763 known antiretroviral status at randomisation
539 no antiretroviral therapy
2 non-HAART antiretroviral therapy
222 HAART
HIV infection status at 6 months
733 known
30 not known
6 infant deaths
24 lost to follow-up
Figure 1: Trial proﬁ le
*Only main cause is listed. †Two ﬁ rst-born twins not eligible, one congenital heart defect, one mother in 
accident, two poor adherence to study procedures, and one mother could not dose competently.
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characteristics of the infants and their mothers did not 
diﬀ er (table 1). At randomisation, 444 (30%) of 
1505 mothers overall were on highly active antiretroviral 
therapy for their own health, increasing to 227 (31%) of 
725 in the extended nevirapine group and 231 (32%) of 
725 in the placebo group at 6 months. Median maternal 
CD4+ lymphocyte counts at randomisation at 6 weeks’ 
postpartum were 528 cells per μL in the extended 
nevirapine group and 557 cells per μL in the placebo 
group. Breastfeeding status was assessed at each study 
visit; more than 95% of infants in both groups were no 
longer breastfed by the 9 month study visit. Time to 
breastmilk cessation diﬀ ered by study site (log-rank 
p<0·0001; data not shown) but not by study group 
(p=0·71; ﬁ gure 2).
Study drug adherence was measured as the proportion 
of infants who were reported to have received all 
scheduled doses since their last follow-up visit. Such 
adherence was 88–96% up to age 6 months and did not 
diﬀ er between sites or study groups. 1446 (97%) of 
1496  infants expected to remain in the study did so at 
6 months and 1180 (94%) of 1259 infants expected to 
remain in the study did so at 12 months; these proportions 
did not diﬀ er between study sites or groups.
Table 2 shows rates of HIV-1 infection and death by 
study group. From Kaplan-Meier analysis, 1·1% 
(95% CI 0·3–1·8) of infants developed postnatal HIV-1 
infection between ages 6 weeks and 6 months in the 
extended nevirapine group compared with 2·4% (1·3–3·6) 
of infants in the placebo group (diﬀ er ence 1·3%, 95% CI 
0–2·6; p=0·049), equating to a 54% reduction in HIV-1 
transmission (ﬁ gure 3). Study interventions stopped at 
age 6 months. Diﬀ erences between study groups were no 
longer signiﬁ cant at 9 months and 12 months of age.
When stratiﬁ ed by mothers who had highly active 
antiretroviral therapy at randomisation, infants born to 
these mothers had low rates of HIV-1 infection, which 
did not diﬀ er by study group at any age, whereas infants 
born to mothers who were not on such therapy had 
signiﬁ cantly lower rates of HIV-1 infection at 6 months 
with extended nevirapine (1·3%) compared with placebo 
(3·4%; p=0·027), but not at 9 or 12 months (table 2). 
Because WHO recommends treatment for women with 
low CD4 cell counts (ie, <350 cells per μL), we did a 
post-hoc analysis that assessed infection rates in infants 
born to mothers with high CD4 cell counts (≥350 cells 
per μL) who were not receiving highly active antiretroviral 
therapy at randomisation. In this subgroup, infants 
randomly allocated to the extended nevirapine group 
had a 6 month HIV-1 infection rate of 0·7%, which is 
much the same as that reported in infants of mothers 
on such therapy, compared with 2·8% for infants in the 
placebo group (p=0·014; diﬀ erence 2·1%, 95% CI 
0·4–3·9), for a 75% reduction in HIV-1 transmission. 
This diﬀ erence continued to be signiﬁ cant at 9 months 
but not at 12 months. However, rates of HIV-1 infection 
did not diﬀ er in infants of women not receiving highly 
Nevirapine group Placebo group
Mothers
n 752 753
Median age (years) 27 (23–30) 27 (23–31)
Marital status
Never married or not living 
with partner
235 (31%) 226 (30%)
Married or living with 
partner
495 (66%) 504 (67%)
Separated or divorced 9 (1%) 11 (2%)
Widowed 13 (2%) 12 (2%)
On HAART at randomisation 221 (29%) 219 (29%)
Median CD4 cell count 
(cells per μl)
528 (371–727) 556·5 (400–755)
WHO classiﬁ cation at randomisation
Stage I 616 (82 %) 630 (84%)
Stage II 105 (14%) 96 (13%)
Stage III 28 (4%) 26 (4%)
Stage IV 3 (<1%) 1 (<1%)
Infants
n 759 763
Sex
Male 363 (48%) 398 (52%)
Female 395 (52%) 365 (48%)
Intersex 1 (<1%) 0
Birthweight (g)
2000–2499 50 (7%) 52 (7%)
2500–2999 214 (28%) 211 (28%)
3000–3499 329 (43%) 336 (44%)
≥3500 166 (22%) 163 (21%)
Missing 0 1 (<1%)
Median 3100 (2800–3400) 3100 (2800–3400)
Data are n, median (IQR), or n (%). HAART=highly active antiretroviral therapy.
Table 1: Baseline characteristics of mothers and infants
Number at risk
Nevirapine
Placebo
0
759
763
100
698
693
200
109
102
300
39
33
400
7
14
Age (days)
0
0·2
0·4
0·6
0·8
1·0
Pr
ob
ab
ili
ty
 o
f b
re
as
tf
ee
di
ng
Extended nevirapine
Placebo
Target age for 6 month
visit (182 days)
Log-rank test p=0·71
Figure 2: Kaplan-Meier analysis of breastfeeding duration, by study group
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active antiretroviral therapy who had low CD4 cell 
counts. Overall survival and HIV-1-free survival did not 
diﬀ er in infants between study groups at 6, 9, or 
12 months (table 2). However, most infant deaths 
occurred after age 6 months and cessation of 
breastfeeding.
Overall, 1259 (83%) of 1519 infants from both groups 
had adverse events (table 3). 125 (16%) of 758 infants given 
extended nevirapine and 116 (15%) of 761 controls had 
serious adverse events. Of 1519 infants who received 
at least one dose of nevirapine or placebo, the most 
common serious adverse events were gastroenteritis in 
81 (5%) infants, pneumonia or bronchopneumonia in 
73 (5%) infants, malaria in 54 (4%) infants, and kwashi or-
kor in 12 (1%) infants, with no signiﬁ cant diﬀ erence 
between study groups. In the 46 infant deaths reported by 
age 12 months (20 in the extended nevirapine group and 
26 in the placebo group), the most frequent associated 
adverse events were gastroenteritis (11 infants) and 
pneumonia or broncho pneumonia (10 infants). Preval-
ence of laboratory abnor malities or rash did not diﬀ er 
between study groups (table 3).
Discussion
After 6 weeks of treatment with once-daily nevirapine, 
continued use of nevirapine to age 6 months in uninfected 
infants of breastfeeding mothers with HIV-1 is safe, and 
results in a greater than 50% reduction in mother-to-child 
transmission from breastfeeding compared with placebo. 
No other study has directly assessed the incre mental 
beneﬁ t of extension of nevirapine from age 6 weeks until 
6 months to establish whether the extended period is 
Extended nevirapine (n=769) Placebo group (n=753) Relative-risk 
reduction
p value*
Endpoints Probability of 
endpoint† (95% CI)
Endpoints Probability of 
endpoint† (95% CI)
All randomly allocated infants
HIV-1 infection
6 months 8/700 1·1% (0·3–1·8) 18/699 2·4% (1·3–3·6) 54% 0·049
9 months 11/692 1·5% (0·6–2·4) 21/683 2·9% (1·7–4·1) 48% 0·078
12 months 15/557 2·1% (1·0–3·1) 22/545 3·0% (1·8–4·2) 30% 0·265
Death
6 months 9/716 1·2% (0·4–2·0) 8/725 1·1% (0·3–1·8) 0% 0·81
9 months 16/703 2·2% (1·1–3·2) 19/705 2·6% (1·4–3·7) 15% 0·61
12 months 20/580 2·8% (1·6–4·0) 26/572 3·6% (2·2–4·9) 22% 0·39
HIV-1 infection or death
6 months 17/706 2·3% (1·2–3·4) 24/707 3·2% (2·0–4·5) 28% 0·27
9 months 26/693 3·6% (2·2–4·9) 39/687 5·3% (3·7–6·9) 32% 0·10
12 months 32/562 4·5% (3·0–6·0) 46/547 6·3% (4·6–8·1) 29% 0·12
Subgroup analyses
Infection from mothers on HAART at randomisation, independent of CD4 cell count
6 months 1/210 0·5% (0–1·4) 0/203 0% 0% ··
9 months 1/169 0·5% (0–1·4) 1/166 0·5% (0–1·4) 0% 0·976
12 months 1/90 0·5% (0–1·4) 1/81 0·5% (0–1·4) 0% 0·976
Infection from mothers not on HAART at randomisation, independent of CD4 cell count
6 months 7/490 1·3% (0·4–2·3) 18/492 3·4% (1·9–5·0) 62% 0·027
9 months 10/483 2·0% (0·8–3·2) 20/480 3·8% (2·2–5·5) 47% 0·071
12 months 14/401 2·8% (1·3–4·2) 21/398 4·0% (2·3–5·7) 30% 0·263
Infection from mothers with high CD4 cell counts (≥350 cells per μL) and not on HAART at randomisation 
6 months 3/418 0·7% (0–1·5) 13/434 2·8% (1·3–4·4) 75% 0·014
9 months 4/414 0·9% (0–1·8) 15/422 3·3% (1·7–4·9) 73% 0·014
12 months 7/340 1·7% (0·4–2·9) 15/346 3·3% (1·7–4·9) 48% 0·116
Infection from mothers with low CD4 cell counts (<350 cells per μL) and not on HAART at randomisation 
6 months 4/71 4·8% (0·2–9·4) 5/54 8·1% (1·3–14·8) 41% 0·438
9 months 6/68 7·5% (1·7–13·3) 5/54 8·1% (1·3–14·8) 7% 0·901
12 months 7/59 8·9% (2·6–15·1) 6/48 9·8% (2·3–17·3) 9% 0·850
Data are cumulative number of events/number at risk unless otherwise stated. HAART=highly active antiretroviral therapy. *Two-sided p value for Z statistic of the diﬀ erence 
in probabilities. †Cumulative rates at 6, 9, and 12 months calculated with Kaplan-Meier methods.
Table 2: Cumulative incidence of HIV-1 infection or death in infants uninfected at age 6 weeks
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more eﬃ  cacious and whether there are increased 
safety issues associated with long-term treatment with 
nevirapine (panel). Our results, in addition to the 
published data for the eﬃ  cacy of 6, 14, and 28 weeks of 
infant nevirapine, show the consistent beneﬁ t and safety 
of nevirapine for prevention of HIV-1 transmission via 
breastfeeding in the ﬁ rst 6 months of life.5–7 We also show 
that, once prophylaxis ends, trans mission risk returns at 
rates much the same as that reported without prophylaxis. 
These ﬁ ndings provide further evidence for the safety and 
eﬃ  cacy of infant nevirapine prophylaxis for 6 months of 
exclusive breast feeding, as is recommended by the WHO. 
Furthermore, these results provide a proof of principle for 
the WHO recommendations to continue infant anti-
retroviral prophylaxis throughout the period of breast-
feeding, whether it lasts 6 months or longer.
The eﬀ ect of the 6 month nevirapine regimen described 
in our study on reduction of HIV-1 breastfeeding 
transmission was especially striking in infants of women 
whose CD4+ cell counts were 350 cells per μL or more 
and who therefore would not qualify for highly active 
antiretroviral therapy for their own health according to 
present WHO criteria.11 In this population of mother-
infant pairs, there was an overall four-fold decrease 
in HIV-1 breastfeeding transmission compared with 
transmission in infants who received placebo from age 
6 weeks to 6 months (0·7% nevirapine vs 2·8% placebo). 
HIV-1 infection rates during extended nevirapine prophy-
laxis in infants born to women with high CD4 cell 
counts who were not receiving highly active antiretroviral 
therapy (0·7%) were much the same as infection rates 
reported in infants born to such women receiving this 
therapy (0·5%).
The importance of identiﬁ cation of and provision of 
therapy to women with low CD4 cell counts is shown by 
the high postnatal HIV-1 transmission rates reported in 
infants born to women not on highly active antiretroviral 
therapy with low CD4 cell counts (<350 cells per μL) 
irrespective of study group. In a study in Zambia,18 88% of 
perinatal and postnatal HIV-1 infections occurred in 
women who met the WHO criteria for receipt of treatment. 
Provision of highly active antiretroviral therapy seems to 
be very eﬀ ective for reduction of postnatal infection in this 
population. Moreover, our study shows that extended 
nevirapine oﬀ ers no additional beneﬁ t compared with 
6 weeks of nevirapine in infants born to women receiving 
highly active antiretroviral therapy, supporting the present 
recommendation by the WHO for only 6 weeks of infant 
prophylaxis for infants of women on such treatement.
Previous studies suggested eﬃ  cacy of other extended 
nevirapine regimens in infants for prevention of 
breastfeeding HIV-1 transmission. The SWEN study5 
showed that once-daily infant nevirapine for 6 weeks 
resulted in a 53% reduction in postnatal HIV-1 infection 
at age 6 weeks compared with single-dose nevirapine 
(HIV-1 infection incidence of 2·5% vs 5·3%, respectively). 
The PEPI-Malawi study6,17 showed that once-daily infant 
nevirapine for 14 weeks resulted in a 69% reduction in 
the risk of postnatal HIV-1 infection at age 14 weeks 
compared with single-dose nevirapine and 1 week of 
infant zidovudine (2·6% vs 8·5%, respectively); however, 
follow-up to 24 months suggested continued trans-
mission after cessation of nevirapine prophylaxis. The 
Breastfeeding and Nutrition study,7 which was under-
taken in Malawi in infants born to mothers with CD4 
cell counts of more than 250 cells per μL, showed that 
postnatal HIV-1 infection in infants uninfected at age 
2 weeks was signiﬁ cantly reduced with 6 months of 
either maternal triple antiretroviral prophylaxis or 
extended infant nevirapine compared with single-dose 
nevirapine (2·9% for triple prophylaxis, 1·7% for 
extended nevirapine, and 5·7% for single-dose nevira-
pine); however, there was not a signiﬁ cant diﬀ erence 
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Figure 3: Kaplan-Meier analysis of cumulative rates of HIV-1 infection, by study group
Overall 
(n=1519)
Extended nevirapine 
group (n=758)
Placebo group 
(n=761)
p value
Adverse events
Infants with at least one adverse event 1259 (83%) 628 (83%) 631 (83%) 0·97
Adverse event possibly related to 
study drug
169 (11%) 87 (12%) 82 (11%) 0·66
Adverse event probably related to 
study drug
16 (1%) 10 (1%) 6 (1%) 0·31
Grade 2B or worse rash 1 (<1%) 1 (<1%) 0 0·499
Abnormal laboratory values*
Infants with at least one laboratory 
assessment
1514 (>99%) 757 (>99%) 757 (99%)
Grade 3 or worse neutropenia  294 (19%) 161 (21%) 133 (18%) 0·07
Grade 3 or higher ALT concentration 6 (<1%) 3 (<1%) 3 (<1%) 1·00
Grade 3 or worse anaemia 354 (23%) 188 (25%) 166 (22%) 0·18
Data are n (%) unless otherwise stated. ALT=alanine aminotransferase. *Some laboratory values were also associated 
with an adverse event.
Table 3: Adverse events, rash, and grade 3 or higher laboratory abnormalities in infants who received at 
least one dose of study drug
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between the extended maternal and infant regimens. 
Eﬃ  cacy of the infant nevirapine regimen in the 
Breastfeeding and Nutrition study7 was 70%, which is 
much the same as that reported with extended nevirapine 
in infants born to mothers with high CD4 cell counts 
(≥350 cells per μL) not receiving highly active 
antiretroviral therapy in our study (6-month HIV-1 
infection rate of 1·1% with extended nevirapine vs 2·4% 
with placebo in infants receiving nevirapine up to 
6 weeks of age). Therefore, the superiority of 6 months 
versus 6 weeks of nevirapine showed in HPTN 046 is 
consistent with the relative reductions in transmission 
reported in each of these studies.
Infant mortality did not diﬀ er signiﬁ cantly between 
study groups in our study. However, most infant deaths 
occurred after age 6 months and nearly all infants stopped 
breastfeeding by 6–9 months of age. Various studies have 
shown increased rates of infant mortality with early 
breastfeeding cessation before the age of 12 months, 
especially in infants born to mothers with low severity 
HIV-1 disease.19–21
Our analyses did not adjust for multiple statistical tests, 
thus increasing the risk of false-positive ﬁ ndings. 
However, because of the higher than expected rate of 
maternal highly active antiretroviral therapy use, we 
reported fewer infant infections than expected, which 
reduced our power to detect diﬀ erences in HIV 
transmission risks between groups.
The major obstacles to PMTCT are the following 
factors: identiﬁ cation of pregnant women with HIV-1 
infection;22 identiﬁ cation of and provision of highly 
active antiretroviral therapy to those women who need 
treatment for their own health (ie, those who have 
highest HIV-1 transmission risk); and provision of 
antiretroviral prophylaxis for those women who do not 
yet qualify for treatment based on WHO guidelines or 
for their infants. An analysis23 of the use of maternal 
triple antiretroviral prophylaxis compared with infant 
nevirapine prophylaxis for PMTCT in women who do 
not need therapy for their own health suggested that 
both interventions reduced the risk of transmission but 
that the cost of maternal prophylaxis was substantially 
greater than was the cost of infant nevirapine. Our study 
suggests the safety and incremental eﬃ  cacy of extension 
of nevirapine to 6 months for prevention of postnatal 
HIV-1 infection in infants of women who do not need 
therapy and also shows the eﬀ ectiveness of highly active 
antiretroviral therapy in reduction of mother-to-child 
transmission in infants born to women with low CD4+ 
cell counts needing therapy. Global elimination of 
paediatric HIV-1 will require a multifaceted approach 
including primary prevention in women of childbearing 
age; prioritisation of eﬀ orts to identify and treat those 
pregnant women with HIV-1 who need therapy for their 
own health (which will beneﬁ t both the woman and 
prevent transmission to her infant); and provision of 
an eﬀ ective prophylaxis regimen such as extended 
nevira pine to infants of women who do not need therapy 
to permit safe, long-term breastfeeding.
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Panel: Research in Context
SystemaƟ c review
We searched PubMed for randomised trials published between September, 2001, and 
September, 2011, without language restriction for papers with the search terms 
“prevention of breastmilk HIV transmission” AND “antiretroviral” and “clinical trials to 
prevent breastmilk HIV transmission”. We identiﬁ ed three randomised trials that assessed 
antiretroviral prophylaxis in infants for 6, 14, or 28 weeks,5–7 and three trials that assessed 
antiretroviral prophylaxis in mothers for 24–28 weeks.7,8,13
Interpretation
Antiretroviral prophylaxis in infants and mothers strikingly reduces postnatal HIV 
transmission. Only one trial7 included infant and maternal antiretroviral prophylaxis 
groups; in this trial no signiﬁ cant diﬀ erence in postnatal 28 week transmission rates 
was noted dependent on who received the treatment (1·7% for infant receipt vs 
2·9% for maternal receipt). Although transmission is continuous during breastfeeding, 
the highest-risk period is probably the ﬁ rst 6–8 weeks of life as suggested by two 
randomised trials published in 2000–03.14–16 The incremental eﬃ  cacy of extension of 
prophylaxis beyond this high-risk period has not been assessed previously; the 
14 week6,17 and 28 week7 infant prophylaxis trials were not designed to address whether 
longer prophylaxis was better in terms of eﬃ  cacy, safety, feasibility, and cost, than was 
a 6 week regimen. HPTN 046 is the ﬁ rst randomised trial to show that extension of 
prophylaxis to 6 months provides signiﬁ cant beneﬁ t compared with shorter courses. 
WHO currently recommends life-long highly active antiretroviral therapy for women 
with low CD4 cell counts (<350 cells per μL) or WHO stage 3–4 disease, and either 
maternal or infant antiretroviral therapy during breastfeeding for 12 months for 
mothers who do not need treatment for their own health.11 However, WHO 
acknowledged the low quality of evidence for this recommendation to extend 
prophylaxis to 12 months.10,11 HPTN 046 provides proof-of-principle data to support 
the WHO recommendation. Furthermore, infant antiretroviral prophylaxis is only 
recommended for infants of women with high CD4 cell counts (≥350 cells per μL) who 
are not currently eligible for highly active antiretroviral therapy. HPTN 046 also 
showed that infant nevirapine prophylaxis is very eﬀ ective in this group, with postnatal 
transmission much the same as that in infants of mothers on highly active 
antiretroviral therapy.
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